期刊文献+

健康教育路径在膝关节置换患者护理中的应用 被引量:13

Effects of Health Education Path for Patients with Knee Replacement
下载PDF
导出
摘要 目的了解健康教育路径在膝关节置换患者护理中的应用效果。方法按入院先后将2009年1月至2011年12月湖州市中心医院收治的行膝关节置换术的90例患者分为观察组和对照组各45例,分别采用健康教育路径及常规方法进行健康教育。结果观察组患者的并发症发生率低于对照组,患者满意率高于对照组,差异均有统计学意义(均P<0.05);观察组和对照组患者的住院时间分别为(14.6±1.9)、(17.8±2.4)d,两组比较,差异有统计学意义(t=5.70,P<0.01)。结论将健康教育路径应用膝关节置换患者护理中,可提高患者的满意率,缩短住院时间,确保健康教育的质量。 Objective To Study the effect of using health education path for patients with knee replace- ment. Methods From January 2009 to December 2011, totally 90 patients with total knee replacement were divided into observational group and control group,with 45 patients in each group. Clinical effects were ob- served by using clinical pathway method or traditional method for the observational group and control group. Results Incidence of postoperative complications in the observational group was lower than that in the control group,while satisfaction rate was higher than that in the control group(P〈0.05). Hospital stay for the observational group and control group were ( 14.6 ± 1.9) d and ( 17.8 ± 2.4) d, respectively, and the difference was significant (t=5. 70, P〈0.01 ). Conclusion Application of health education pathway may contribute to improving patient satisfaction, shortening the length of stay and guaranteeing the quality of health education.
作者 陈俊晶
出处 《解放军护理杂志》 CSCD 2013年第21期50-52,共3页 Nursing Journal of Chinese People's Liberation Army
关键词 健康教育路径 膝关节置换 护理 health education path knee replacement nursing
  • 相关文献

参考文献4

二级参考文献13

共引文献874

同被引文献152

  • 1王攀.利伐沙班与低分子肝素预防人工全膝关节置换术后深静脉血栓形成的研究[J].中国医学前沿杂志(电子版),2014,6(4):111-114. 被引量:16
  • 2李艳霞.择期纤维支气管镜检查术前护理需求及遵医行为[J].国际医药卫生导报,2006,12(18):104-106. 被引量:8
  • 3刘联群.骨伤科专病护理路径[M].北京:人民卫生出版社,2010:P24-26.
  • 4Schneeweiss S, Gagne J J, Patrick AR, et al. Comparative efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atdtal fibriUation using network metaanalysis I nt Angiol. 2012;31 (4):330-339.
  • 5Kennedy B, GargoumFS, Kennedy L, et al. Emerging articoagulants. Curr Med Chem. 2012;19(20):3388- 3416.
  • 6Brinkman HJ. Global assays and the management of oral anticoagulation. Thromb J. 2015; 13:9.
  • 7Jourdi G, Siguret V, Martin AC, et al. Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban. Thromb Haemost. 2015; 113(6).
  • 8Farag M, Gorog DA. Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial. Future Cardiol. 2015;11(2):147-151.
  • 9Washam JB, Stevens SR, Lokhnygina Y, et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet. 2015. doi: 10.1016/S0140-6736(14)61836-5.
  • 10Laliberte F, Cloutier M, Crivera C, et al. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users. Clin Ther. 2015. doi: 10.1016/j.clinthera.2015.02.001.

引证文献13

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部